RGS9-2: probing an intracellular modulator of behavior as a drug target

Trends in Pharmacological Sciences

Volumn 30, Issue 3, 2009, Pages 105-111

  Traynor, John R ^a   Terzi, Dimitra ^b   Caldarone, Barbara J ^c   Zachariou, Venetia ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CRETE   (Greece)

^c PSYCHOGENICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; LEVODOPA; MU OPIATE RECEPTOR; NEUROLEPTIC AGENT; PROTEIN RGS9 2; PSYCHOSTIMULANT AGENT; QUINPIROLE; RESERPINE; RGS PROTEIN; RGS2 PROTEIN; RGS4 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ARTICLE; CORPUS STRIATUM; DRUG TARGETING; DYSKINESIA; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DYSKINESIA, DRUG-INDUCED; HUMANS; OPIOID-RELATED DISORDERS; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID, MU; REWARD; RGS PROTEINS; SIGNAL TRANSDUCTION;

EID: 61349171291     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.11.006     Document Type: Article

References (38)

1. Robbins T.W., et al. Limbic-striatal interactions in reward-related processes. Neurosci. Biobehav. Rev. 13 (1989) 155-162
2. Picconi B., et al. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology 26 (2005) 779-783
3. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59 (2006) 1151-1159
4. Everitt B.J., and Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8 (2005) 1481-1489
5. Hepler J.R., and Gilman A.G. Trends Biochem. Sci 17 (1992) 383-387
6. Dohlman H.G., et al. Sst2, a negative regulator of pheromone signaling in the yeast Saccharomyces cerevisiae: expression, localization, and genetic interaction and physical association with Gpa1 (the G-protein α subunit). Mol. Cell. Biol. 16 (1996) 5194-5209
7. Ross E.M., and Wilkie T.M. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu. Rev. Biochem. 69 (2000) 795-827
8. qα and block activation of phospholipase Cβ by γ-thio-GTP-Gq-α. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 428-432
9. Richman R.W., et al. GS12 interacts with the SNARE-binding region of the Cav2.2 calcium channel. J. Biol. Chem. 280 (2005) 1521-1528
10. Gold S.J., et al. Regulators of G protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. J. Neurosci. 17 (1997) 8024-8037
11. Neubig R.R., and Siderovski D.P. Regulators of G-protein signaling as new central nervous system drug targets. Nat. Rev. Drug Discov. 1 (2002) 187-197
12. B receptors and GIRK channels in dopamine neurons of the ventral tegmental area. Nat. Neurosci. 10 (2007) 1559-1568
13. Charlton J.J., et al. Multiple actions of spinophilin modulate mu opioid receptor function. Neuron 58 (2008) 238-247
14. Chase D.L., et al. Mechanism of extrasynaptic dopamine signaling in Caenorhabditis elegans. Nat. Neurosci. 7 (2004) 1096-1103
15. Hooks S.B., et al. A role of RGS proteins in drug addiction. Biochem. Pharmacol. 75 (2008) 76-84
16. Levitt P., et al. Making the case for a candidate vulnerability gene in schizophrenia: convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol. Psychiatry 60 (2005) 534-537
17. Nishiguchi K.M., et al. Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation. Nature 427 (2004) 75-78
18. Martemyanov K.A., et al. R7BP, a novel neuronal protein interacting with RGS proteins of the R7 family. J. Biol. Chem. 280 (2005) 5133-5136
19. Witherow D.S., et al. Complexes of the G protein subunit Gβ5 with the regulators of G protein signaling RGS7 and RGS9. Characterization in native tissues and in transfected cells. J. Biol. Chem. 275 (2000) 24872-24880
20. Chen C.K., et al. Instability of GGL domain-containing RGS proteins in mice lacking the G protein β-subunit Gβ5. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6604-6609
21. i family G proteins with differential selectivity and maximal activity. J. Biol. Chem. 278 (2003) 10087-10093
22. Rahman Z., et al. Cloning and characterization of RGS9-2, a striatal enriched alternatively sliced product of the RGS9 gene. J. Neurosci. 19 (1999) 2016-2026
23. Rahman Z., et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 38 (2003) 941-952
24. 2 dopamine receptors colocalize regulator of G protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knockout mice develop dyskinesias associated with dopamine pathways. J. Neurosci. 25 (2005) 2157-2165
25. Zachariou V., et al. Essential role for RGS9 in opiate action. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13656-13661
26. Blundell J., et al. Motor coordination deficits in mice lacking RGS9. Brain Res. 1190 (2008) 78-85
27. Psifogeorgou K., et al. RGS9 is a negative modulator of μ opioid receptor function. J. Neurochem. 103 (2007) 617-625
28. Gold S.J., et al. Regulation of RGS proteins by chronic morphine in rat locus coeruleus. Eur. J. Neurosci. 17 (2003) 971-980
29. 2 dopamine receptors. J. Neurochem. 96 (2006) 1606-1615
30. Clark M.J., et al. Endogenous RGS protein action modulates μ-opioid signaling through Gαo. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways. J. Biol. Chem 278 (2003) 9418-9425
31. Clark M.J., and Traynor J.R. Endogenous regulator of G protein signaling proteins reduce μ-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells. J. Pharmacol. Exp. Ther. 312 (2005) 809-815
32. 2 receptor coupling to Gαo proteins and Ca2+ responses in CHO-K1 cells. FEBS Lett 533 (2003) 67-71
33. Gold S.J., et al. RGS9-2 negatively modulates l-3, 4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J. Neurosci. 27 (2007) 14338-14348
34. 2 dopamine receptor-mediated Ca2_ channel inhibition in rat striatal cholinergic interneurons. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16339-16344
35. Clark M.J., et al. Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model. Mol. Pharmacol. 73 (2008) 1538-1548
36. Jin Y., et al. Structure-based design, synthesis, and activity of peptide inhibitors of RGS4 GAP activity. Methods Enzymol. 389 (2004) 266-277
37. Roman D.L., et al. Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol. Pharmacol. 71 (2007) 169-175
38. Traynor J.R., and Neubig R.R. Regulators of G protein signaling and drugs of abuse. Mol. Interv. 5 (2005) 30-41